Mar 16, 2023 / 02:00PM GMT
Unidentified Analyst -
Good morning. So the next company here is Exelixis. I'm pleased to welcome Andrew Peters, SVP of Strategy. Peters, welcome, and thanks for joining us.
Andrew Ross Peters - Exelixis, Inc. - SVP of Strategy
Yes, thanks for having me.
Questions and Answers:
Unidentified Analyst -So CABOMETYX has obviously been a huge commercial success for Exelixis in -- over the last year, a few years. At this point, how should we think about growth drivers as we head into 2023?
Andrew Ross Peters - Exelixis, Inc. - SVP of Strategy
Yes. So I guess just everyone, thanks for having me here. This is a great event. As a reminder, I'll be making some forward-looking statements today. So please see relevant SEC filings for appropriate disclosures.
So yes, Cabo, obviously, great product. One of the things that we talk about a lot internally is really what drives Cabo is a great team, great data. And we can point to something like the 44-month update at the recent ASCO GU
Trustpilot
